Related Experiment Videos
Summary
Parkinson disease patients show normal prolactin levels and responses to levodopa. However, their response to thyrotropin-releasing hormone (TRH) is blunted after Sinemet, suggesting extrastriatal dopamine system pathology.
Area of Science:
- Neuroendocrinology
- Pituitary Gland Physiology
- Dopamine System Function
Background:
- Dopaminergic pathways significantly influence anterior pituitary lactotroph cell function.
- Parkinson disease is characterized by the degeneration of dopaminergic neurons, primarily in the substantia nigra.
Purpose of the Study:
- To investigate the dopaminergic control of lactotroph cells in Parkinson disease patients.
- To assess prolactin secretion and response to thyrotropin-releasing hormone (TRH) in individuals with Parkinson disease.
Main Methods:
- Studied prolactin levels and TRH-stimulated responses in parkinsonian patients and age-matched controls.
- Administered levodopa, Sinemet (levodopa plus carbidopa), and bromocriptine to assess hormonal changes.
Main Results:
- Resting prolactin levels and TRH-induced prolactin rise were normal in Parkinson disease.
- Levodopa normally suppressed prolactin; however, TRH response was attenuated after Sinemet or bromocriptine.
- Carbidopa addition enhanced levodopa's prolactin suppression, indicating central dopamine formation.
Conclusions:
- Findings suggest pathology in extrastriatal dopamine systems in Parkinson disease.
- Exogenous levodopa likely acts via central dopamine formation within the blood-brain barrier, not direct peripheral effects.